Chronic viral hepatitis B without delta-agent (B18.1) is a persistent infection with the hepatitis B virus (HBV) that has lasted for six months or longer. It is clinically defined by the continued presence of the hepatitis B surface antigen (HBsAg) in the blood. Chronic HBV infection is a significant global health burden and a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). The clinical course of the disease is highly variable, often progressing through several immunopathological phases including the immune-tolerant phase, the immune-active phase (HBeAg-positive or HBeAg-negative), and the inactive carrier state. This specific classification (B18.1) denotes that the patient is not co-infected or super-infected with the hepatitis delta virus (HDV), which typically accelerates liver damage. Long-term management focuses on monitoring viral load (HBV DNA levels), liver enzymes (ALT/AST), and screening for liver fibrosis and malignancy.
Explicitly state the chronicity of the Hepatitis B infection by documenting its persistence for greater than six months.
Example: Patient is a 45-year-old male with confirmed chronic viral hepatitis B without delta-agent, documented by persistent HBsAg for 12 months. Current management involves Tenofovir Alafenamide 25mg daily. Liver ultrasound shows no evidence of cirrhosis, and the patient remains in a chronic compensated state.
Billing Focus: Chronicity documentation supports the use of B18.1 rather than B16 codes for acute infections.
Always document the presence or absence of the Hepatitis Delta virus co-infection.
Example: The patient has chronic viral hepatitis B without delta-agent as confirmed by negative anti-HDV IgG and IgM testing. No evidence of superinfection or co-infection is present at this time.
Billing Focus: Directly distinguishes B18.1 from B18.0, which requires the presence of the delta-agent.
Link chronic hepatitis B to any associated manifestations such as cirrhosis or hepatocellular carcinoma using causal language.
Example: Chronic viral hepatitis B without delta-agent has progressed to compensated cirrhosis of the liver without ascites. Patient is monitored every 6 months with AFP and RUQ ultrasound for HCC screening.
Billing Focus: Supports the use of multiple codes for manifestation-etiology relationships (e.g., K74.60).
Document the HBeAg status and HBV DNA viral load to indicate the phase of chronic infection.
Example: Patient exhibits chronic viral hepatitis B without delta-agent, HBeAg-positive with a viral load of 2.5 million IU/mL, indicating active viral replication. Liver enzymes are mildly elevated at ALT 68 U/L.
Billing Focus: Supports medical necessity for high-intensity monitoring and specialized antiviral treatment.
Identify the patient as a chronic carrier versus having active chronic hepatitis based on inflammatory activity.
Example: Patient is a chronic carrier of hepatitis B virus without delta-agent, with normal ALT levels and low HBV DNA (under 2000 IU/mL) over the last three visits, indicating an inactive carrier state.
Billing Focus: Differentiates between B18.1 and the carrier state Z22.51, though B18.1 is preferred if chronic infection is clinically managed.
Used for routine follow-up of a stable chronic hepatitis B patient not currently experiencing complications.
Appropriate when managing B18.1 with new lab abnormalities, adjusting antiviral medications, or assessing for progression.
Used for complex HBV cases with severe manifestations like cirrhosis, renal impairment from therapy, or liver cancer screening.
Essential for monitoring the viral load and response to antiviral therapy in chronic B18.1 patients.
Primary diagnostic test to confirm the presence of the virus.
Used to assess liver fibrosis stages in chronic HBV patients without the need for biopsy.
Used when non-invasive tests are inconclusive regarding liver inflammation or fibrosis level.
Standard screening for hepatocellular carcinoma every 6 months in chronic HBV patients.
Often ordered alongside imaging for HCC surveillance in chronic HBV patients.
Helps distinguish between chronic infection and past exposure or vaccination.